Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 314 results for breast cancer

  1. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

    Retired guideline

  3. Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development Reference number: GID-TA11487 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    In development Reference number: GID-TA11862 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development Reference number: GID-TA11439 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Breast cancer

    All NICE products on breast cancer. Includes any guidance, advice and quality standards.

    Topic page

  7. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]

    In development Reference number: GID-TA11773 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Interstitial laser therapy for breast cancer (IPG89)

    We have moved interventional procedures guidance 89 to become HealthTech guidance 55. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Early and locally advanced breast cancer: diagnosis and treatment (CG80)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guideline

  10. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Withdrawn guidance

  11. Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)

    This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.

    Withdrawn guidance

  12. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  13. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  14. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  15. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance